Evidence map›Paper›PMID 26909542›Full record

ArticleAmerican journal of respiratory cell and molecular biology2016

Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice.

Gloria S Forkuo, Hosu Kim, Vaidehi J Thanawala, Nour Al-Sawalha, Daniel Valdez, Radhika Joshi, Sergio Parra, Tonio Pera, Patricia A Gonnella, Brian J Knoll and 3 more

Abstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. [Mendelian Randomization Analysis of Potential Molecular Targets for Type 2 Airway Inflammatory Diseases].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Article
  3. Review
  4. Identification of a β-arrestin-biased negative allosteric modulator for the βProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  5. In silico identification of a βProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  6. PD 102807 Induces M3 mAChR-Dependent GRK-/Arrestin-Biased Signaling in Airway Smooth Muscle Cells.American journal of respiratory cell and molecular biology · 2022
    Article
  7. βBritish journal of pharmacology · 2022
    Article
  8. Can GPCRs Be Targeted to Control Inflammation in Asthma?Advances in experimental medicine and biology · 2021
    Article
  9. Roflumilast Suppresses Adipogenic DifferentiationFrontiers in endocrinology · 2021
    Article
  10. Therapeutic Potential of Targeting ß-Arrestin.Frontiers in pharmacology · 2019
    Review
  11. Article
  12. Article
  13. Article
  14. Biased signaling of the proton-sensing receptor OGR1 by benzodiazepines.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018
    Article
  15. Article
  16. Article
  17. Understanding how long-acting βBritish journal of pharmacology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Gloria S Forkuo1 Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas.
Hosu Kim1 Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas.
Vaidehi J Thanawala1 Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas.
Nour Al-Sawalha1 Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas.
Daniel Valdez2 Department of Biology and Biochemistry, University of Houston, Houston, Texas.
Radhika Joshi1 Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas.
Sergio Parra3 Vapogenix, Inc., Houston, Texas.
Tonio Pera4 Center for Translational Medicine and Jane and Leonard Korman Lung Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and.
Patricia A Gonnella4 Center for Translational Medicine and Jane and Leonard Korman Lung Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and.
Brian J Knoll1 Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas.
Julia K L Walker5 Duke University School of Nursing, Duke University Medical Center, Durham, North Carolina.
Raymond B Penn4 Center for Translational Medicine and Jane and Leonard Korman Lung Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and.
Richard A Bond1 Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas.
University of Houston · USThomas Jefferson University · USDuke University · USPhysioGenix (United States) · US

Funding

G Protein-Coupled Receptor Signaling in Airway Smooth MuR01HL058506 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI RAYMOND B. PENN · 2001 to 2026
$9.3M
Optimizing Beta-Adrenoceptor Signaling Bias in AsthmaR01AI110007 · NIAID · DUKE UNIVERSITY · PI BOND, RICHARD AGUSTIN, PENN, RAYMOND B. · 2014 to 2018
$3.2M
NHLBI NIH HHS R01 HL058506NIAID NIH HHS R01 AI110007
6 · The paper itself

Abstract

Mice lacking the endogenous β2-adrenoceptor (β2AR) agonist epinephrine (phenylethanolamine N-methyltransferase [PNMT]-knockout mice) are resistant to developing an "asthma-like" phenotype in an ovalbumin sensitization and challenge (Ova S/C) model, and chronic administration of β2AR agonists to PNMT-KO mice restores the phenotype. Based on these and other studies showing differential effects of various β2AR ligands on the asthma phenotype, we have speculated that the permissive effect of endogenous epinephrine and exogenous β2AR agonists on allergic lung inflammation can be explained by qualitative β2AR signaling. The β2AR can signal through at least two pathways: the canonical Gαs-cAMP pathway and a β-arrestin-dependent pathway. Previous studies suggest that β-arrestin-2 is required for allergic lung inflammation. On the other hand, cell-based assays suggest antiinflammatory effects of Gαs-cAMP signaling. This study was designed to test whether the in vitro antiinflammatory effects of phosphodiesterase 4 inhibitors, known to increase intracellular cAMP in multiple airway cell types, attenuate the asthma-like phenotype produced by the β2AR agonists formoterol and salmeterol in vivo in PNMT-KO mice, based on the hypothesis that skewing β2AR signaling toward Gαs-cAMP pathway is beneficial. Airway inflammatory cells, epithelial mucus production, and airway hyperresponsiveness were quantified. In Ova S/C PNMT-KO mice, formoterol and salmeterol restored the asthma-like phenotype comparable to Ova S/C wild-type mice. However, coadministration of either roflumilast or rolipram attenuated this formoterol- or salmeterol-driven phenotype in Ova S/C PNMT-KO. These findings suggest that amplification of β2AR-mediated cAMP by phosphodiesterase 4 inhibitors attenuates the asthma-like phenotype promoted by β-agonists.

Indexed as

Adrenergic beta-2 Receptor AgonistsAminopyridinesAnimalsAsthmaBenzamidesBronchial HyperreactivityCyclopropanesDrug Therapy, CombinationEosinophilsFormoterol FumarateInflammationLungMiceMice, KnockoutMucusPhenotypeAdrenergic beta-2 Receptor AgonistsAminopyridinesBenzamidesCyclopropanesFormoterol FumaratePhenylethanolamine N-MethyltransferasePhosphodiesterase 4 InhibitorsRoflumilastasthma modelbiased signalingβ2-adrenoceptor

Identifiers

PMID26909542
PMCPMC4979368
OpenAlexW2484529140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.